The number of innovative Chinese medicine drugs approved this year exceeded double digits for the first time, hitting a new high in the calendar year. Beijing News Drafting/Xu Xiao
With the approval of the Innovative Chinese Medicines Huzhen Qingfeng Capsule and The Depression Relief Capsules for the Marketing in December this year, the number of innovative Chinese medicine drugs approved this year exceeded double digits for the first time, covering respiratory, neurological, digestive and other fields. This year, favorable policies to support the development of traditional Chinese medicine have been frequently introduced, involving the promotion of inheritance and innovation and the improvement of the quality of traditional Chinese medicines, and the centralized procurement of the Interprovincial Alliance of Proprietary Chinese Medicines. Liu Zhanglin, vice president of the China Association of Chinese Medicines, believes that "the Chinese medicine industry is facing a good opportunity that has never been seen before. ”
According to the incomplete statistics of the Beijing News reporter, in 2020, the State Food and Drug Administration launched a total of 3 traditional Chinese medicine innovations, namely The Lianhua Light Cough Tablets of Yiling Pharmaceutical, the PainKill PainKiller Gel of Kangyuan Pharmaceutical, and the Mulberry Total Alkaloid Tablets of Wuhe Boao. As of December 30, 2021, the number of innovative Chinese medicine drugs approved this year has reached 11, becoming the most approved chinese medicine innovative drugs in the past five years, more than the total number of approved Chinese medicine drugs in 2017-2020.
In March this year, the State Food and Drug Administration approved the listing of lung detoxification granules from the Institute of Clinical Basic Medicine of Traditional Chinese Medicine of the Chinese Academy of Chinese Medical Sciences, the wet sepsis granules of Guangdong Yifang Pharmaceutical, and the Xuan lung septic granules of Shandong Buchang Pharmaceutical through special approval procedures. These three chinese medicines are all derived from ancient classic recipes, which are the results of the transformation of effective prescription drugs to clear the lungs and detoxification soup, wet septic poison formulas and xuan lung septic poisoning recipes screened by many academicians and experts in the frontline of wuhan anti-epidemic clinic since the outbreak of the new crown pneumonia epidemic, and are also the first varieties reviewed and approved in accordance with the "Requirements for The Registration Classification and Declaration of Chinese Medicines" after the reform of the registration classification of Chinese medicines.
Kangyuan Pharmaceutical Yinqiao Qing Fever Tablets is an innovative chinese medicine drug developed on the basis of clinical experience, and has carried out multi-center, randomized, double-blind, placebo/positive drug parallel control clinical trials, and the results show that it can be used for the treatment of external wind fever type common cold. The State Food and Drug Administration said that the new Chinese medicine drug is on the market, providing a new treatment option for patients with common colds.
JieYu debounciation capsule is based on the clinical experience of Ling Pharmaceutical developed on the basis of the innovative chinese medicine drug, the prescription according to the classic work of Chinese medicine "Golden Kuai Compendium" recorded in the half-summer Magnolia soup and "Typhoid Fever" recorded in the gardenia Magnolia soup cut, to carry out random, double-blind, positive control drugs (chemicals), placebo parallel control, multi-center clinical trials, the results show that it can be used for mild and moderate depression in TCM dialectical treatment of qi depression phlegm obstruction, depression internal disturbance.
Global growth consultancy Frost & Sullivan ("Sullivan") predicts that by 2022, the market size of China's Traditional Chinese medicine industry is expected to reach 1.04 trillion yuan. According to public data, in China's medical insurance catalogue over the years, the number of traditional Chinese medicines has grown rapidly, with 1321 proprietary Chinese medicines in the 2019 edition of the medical insurance catalogue, which is the same as the number of Western medicines, and 1374 in 2021.
This year, favorable policies to support the development of traditional Chinese medicine have also been frequently introduced. For example, the Notice on Several Policies and Measures to Accelerate the Development of Traditional Chinese Medicine Characteristics, the Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine, the Implementation Plan for the Action of Dissemination of Chinese Medicine Culture (2021-2025), and the Requirements for the Registration Classification and Declaration of Chinese Medicines.
Beijing News reporter Zhang Xiulan
Proofread by Zhao Lin